Comparison 7. Nitrates vs Direct Vasodilator.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Total Serious Adverse Events	0	0	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
2 All‐cause mortality	0	0	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
3 Non‐fatal cardiovascular events	0	0	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
4 Acute Myocardial Infarction	0	0	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
5 Respiratory insufficiency requiring mechanical ventilation	0	0	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
6 Withdrawals due to adverse events	0	0	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
7 Mean change in systolic blood pressure during treatment	1	24	Mean Difference (IV, Fixed, 95% CI)	‐3.67 [‐20.41, 13.07]
7.1 Nitroglycerine vs. Hydralazine	1	24	Mean Difference (IV, Fixed, 95% CI)	‐3.67 [‐20.41, 13.07]
8 Mean change in diastolic blood pressure during treatment	1	24	Mean Difference (IV, Fixed, 95% CI)	3.34 [‐4.82, 11.50]
8.1 Nitroglycerine vs. hydralazine	1	24	Mean Difference (IV, Fixed, 95% CI)	3.34 [‐4.82, 11.50]
9 Mean change in heart rate during treatment	1	24	Mean Difference (IV, Fixed, 95% CI)	‐5.34 [‐20.65, 9.97]
9.1 Nitroglycerine vs. hydralazine	1	24	Mean Difference (IV, Fixed, 95% CI)	‐5.34 [‐20.65, 9.97]